|
|
|
MIRA
INFORM REPORT
|
Report No. : |
505479 |
|
Report Date : |
24.04.2018 |
IDENTIFICATION DETAILS
|
Name : |
DONGYING TIANDONG PHARMACEUTICAL CO.,LTD |
|
|
|
|
Registered Office : |
No-1236, Nan-Er Road, Dongying Dist. Dong Ying City, Shandong Province, Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2016 |
|
|
|
|
Date of Incorporation : |
22.12.1992 |
|
|
|
|
Credibility Code : |
91370500613376668H |
|
|
|
|
Legal Form : |
Chinese-foreign equity joint venture enterprise |
|
|
|
|
Line of Business : |
The subject’s registered business scope includes manufacturing and
selling small volume injection, API; purchasing and processing pig's small
intestine and its semi-finished products (with permit if needed) |
|
|
|
|
No. of Employees : |
190 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state support of key sectors, and a restrictive investment regime. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2016 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.
After keeping its currency tightly linked to the US dollar for years, China in July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing announced it would allow a resumption of gradual liberalization. From 2013 until early 2015, the renminbi (RMB) appreciated roughly 2% against the dollar, but the exchange rate fell 13% from mid-2015 until end-2016 amid strong capital outflows in part stemming from the August 2015 official devaluation; in 2017 the RMB resumed appreciating against the dollar – roughly 7% from end-of-2016 to end-of-2017. From 2013 to 2017, China had one of the fastest growing economies in the world, averaging slightly more than 7% real growth per year. In 2015, the People’s Bank of China announced it would continue to carefully push for full convertibility of the renminbi, after the currency was accepted as part of the IMF’s special drawing rights basket. However, since late 2015 the Chinese Government has strengthened capital controls and oversight of overseas investments to better manage the exchange rate and maintain financial stability.
The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) managing its high corporate debt burden to maintain financial stability; (c) controlling off-balance sheet local government debt used to finance infrastructure stimulus; (d) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (e) dampening speculative investment in the real estate sector without sharply slowing the economy; (f) reducing industrial overcapacity; and (g) raising productivity growth rates through the more efficient allocation of capital and state-support for innovation. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China’s population control policy known as the “one-child policy” - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese Government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.
The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made more progress on subsidizing innovation than rebalancing the economy. Beijing has committed to giving the market a more decisive role in allocating resources, but the Chinese Government’s policies continue to favor state-owned enterprises and emphasize stability. Chinese leaders in 2010 pledged to double China’s GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the “dominant” role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time. The slight acceleration in economic growth in 2017—the first such uptick since 2010—gives Beijing more latitude to pursue its economic reforms, focusing on financial sector deleveraging and its Supply-Side Structural Reform agenda, first announced in late 2015.
|
Source : CIA |
Company name and address
Company Name : DONGYING TIANDONG PHARMACEUTICAL CO.,LTD
Address : NO-1236, NAN-ER ROAD, DONG YING CITY,
SHANDONG PROVINCE, PR CHINA
Telephone : 0086- 546-7791088
Facsimile : 0086- 546-8180302
Website : http://www.td-pharm.com/
Email : market@td-pharm.com
REGISTRATION
INFORMATION
Established Date : 1992-12-22
Credibility Code : 91370500613376668H
Legal Form : Chinese-foreign equity joint venture
enterprise
Registration Authority : Administration for Industry & Commerce (AIC) - Dongying
Status : Active
Registered Capital : RMB 20,720,000
Paid Up Capital : RMB
20,720,000
Turnover : RMB 159,120,000 (as of Dec. 31, 2016)
Equities : RMB
141,660,000 (as of Dec. 31, 2016)
Chief Executive : Guo
Lin
Business Line : Manufacturer
Manpower : 190
Tax Registration
Certificate No. : 91370500613376668H
Organization Code : 61337666-8
HS code :
3705932102
Import & Export code : 3700613376668
Financial
Condition : Fairly
Stable
Business Size : Medium Enterprise
Payment : Regular
Registered Address
NO-1236, NAN-ER ROAD, dongying dist. DONG YING CITY, SHANDONG PROVINCE, PR CHINA
Company Status: Chinese-foreign equity joint venture enterprise
This form of business in PR China is defined as a legal person. It is a
limited co. jointly invested by one or more foreign companies and one or more
PR China controlled companies within the territories of PR China according to a
certain proportion of capital investment. The investing parties exercise
business management, share profits and bear all risks and liabilities of the
co. together. The equity joint venture law requires that foreign party
contribute not less than 25% of the registered capital, with no maximum. The
investing parties are free to agree on method of profit distribution and
liabilities bearing according to the proportion of capital investment. Each
investing parties contributes funds, tangible assets, technology & etc. The
board of directors excises the high authority. The joint venture usually has a
limited duration of 10 to 50 years. Enterprise with large investment, long
construction periods, low investment returns, introducing of advanced
technology & advanced technology products that have good competition
position in international market may extend beyond the 50 years limit.
Premise
The subject operates from premises located at
the heading address, and this address houses its operating office and factory
in Dongying. Our checks reveal that the subject rents the total premise, but
the square meters are unknown.
MANAGEMENT
|
Position |
Name |
Nationality |
|
Legal representative, General Manager |
Guo Lin |
Chinese |
|
Chairman |
Yang Xiaohong |
Chinese |
|
Directors |
Zhang Zaizhong Guo Lin Liu Dongguang Liu Qingyi |
Chinese |
MAJOR
SHAREHOLDERS
Name % Shareholding
Shandong Hi-Tech Chemical Industry Group Co., Ltd. 58.51%
Permanent Brilliance Group International Limited (HK) 25.08%
Shandong Hi-Tech Chemical Trading Co.,Ltd. 16.41%
Shandong Hi-Tech Chemical Industry Group Co., Ltd.
------------------------------------------
Credibility Code: 91370500164802990E
Legal representative: Wang Jie
Registered Capital: RMB 115,000,000
Established Date: 2006-04-18
KEY EVENTS
Changes of its registered information are as
follows:
|
Date of change |
Item |
Before the change |
After the change |
|
2015-07-03 |
Legal representative |
Yang Xiaohong |
Present one |
BUSINESS
OPERATIONS
The subject’s registered business scope includes manufacturing and
selling small volume injection, API; purchasing and processing pig's small
intestine and its semi-finished products (with permit if needed)
The subject is mainly engaged in
manufacturing and selling pharmaceuticals & API.
Products:
Nadroparin calcium
Dalteparin sodium
Heparin sodium
Enoxaparin sodium
Heparin sodium preparation
The
subject sources its materials 60% from domestic market, and 40% from overseas
market. the subject sells 30% of its products in domestic market, and 70% to
overseas market, mainly Russia, Ukraine, etc.
The
buying terms of the subject include Check, T/T, L/C and Credit of 30-60 days.
The payment terms of the subject include Check, T/T, L/C and Credit of 30-60
days.
SUPPLIER & CUSTOMER
No record.
RELATED COMPANIES
Subsidiaries
Dongying Hengyi Engineering Project Management
Co., Ltd.
========================
Credibility Code: 91370502MA3CDAU107
Legal representative: Guo Lin
Registered Capital: RMB 20,400,000
Established Date: 2016-07-06
NEGATIVE
INFORMATION
Lawsuit Record: No record.
Trade payment experience: The subject did not provide any name of trade/service suppliers and
we have no other sources to conduct the enquiry at present.
Delinquent payment record: None in our database.
Debt collection record: No overdue amount owed by the subject was placed to us for collection
within the last 6 years.
Customs
administrative penalty: No record.
Equity freeze
information: No record.
Administrative Penalty: No record.
MORTGAGE
There is no record of mortgage information at
present.
TRADEMARK
|
Registration Date |
Trademark Design |
|
|
9915077 |
2011-08-31 |
|
|
9915090 |
2011-08-31 |
|
PATENT
|
Patent name |
Published Application Number |
Application number |
Date of publication |
|
An improved ultrasonic low temperature
extraction tank |
CN205307863U |
CN201620014757.0 |
2016-06-15 |
|
Refining process of high performance
heparin sodium |
CN105399865A |
CN201410467828.8 |
2016-03-16 |
BANKING
Agricultural Bank of China Dongying Dist. Subbranch Business Department
Account No.: 312001040000698
ABBREVIATED
FINANCIAL STATEMENT
Financial Summary
===============
Unit: RMB’000
|
|
As
of Dec. 31, 2015 |
As
of Dec. 31, 2016 |
|
Total assets |
321,541 |
365,740 |
|
|
========= |
========= |
|
Total liabilities |
181,961 |
224,080 |
|
Equities |
139,580 |
141,660 |
|
|
-------------- |
-------------- |
|
Total liabilities & equities |
321,541 |
365,740 |
|
|
========= |
========= |
|
Turnover |
154,419 |
159,120 |
|
Profits before tax |
18,011 |
2,540 |
|
Less: tax |
2,783 |
460 |
|
Profits |
15,228 |
2,080 |
Important Ratios
=============
|
|
As
of Dec. 31, 2015 |
As
of Dec. 31, 2016 |
|
*Liabilities to assets |
0.57 |
0.61 |
|
*Net profit margin (%) |
9.86 |
1.31 |
|
*Return on total assets (%) |
4.74 |
0.57 |
|
*Turnover/Total assets |
0.48 |
0.44 |
PROFITABILITY:
AVERAGE
The turnover of the subject appears fairly good in its line.
the subject’s net profit margin is fairly good in 2015 and average in
2016.
the subject’s return on total assets is average.
the subject’s turnover is in a fair level, comparing with the size of
its total assets.
LEVERAGE: AVERAGE
The debt ratio of the subject is average.
The risk for the subject to go bankrupt is average.
TREND ANALYSIS
===========
|
|
2014 |
2015 |
2016 |
|
Sales Trend |
-- |
-- |
Ç |
|
Profit margin |
-- |
-- |
È |
|
Debt to assets ratio |
-- |
-- |
Ç |
|
Overall Financial
Condition |
□Good □Fairly Good □Stable ■Fairly Stable □Fair □Poor |
||
COMMENT
The subject was registered as a Chinese-foreign equity joint venture
enterprise at local Administration for Industry & Commerce (AIC - The
official body of issuing and renewing business license).
The subject is considered medium-sized in its line with fairly stable
financial conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 66.22 |
|
|
1 |
INR 92.84 |
|
Euro |
1 |
INR 81.27 |
|
CNY |
1 |
INR 10.53 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
PRA |
|
|
|
|
Report Prepared
by : |
SYL |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.